Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02414854 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
A Phase 3 study of Asthma, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,902
- Enrollment target
- 20
- Study locations
NCT02414854: Completed Phase 3 study of Asthma, sponsored by Sanofi.
NCT02414854 is a Phase 3 study of Asthma that has completed, run by Sanofi. The registered enrollment target is 1,902 participants, above the 1,558-participant average among 374 other Asthma trials with a reported enrollment target (22% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02414854, a Phase 3 study of Asthma, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,902 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Objective: To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent asthma. Secondary Objectives: * To evaluate the safety and tolerability of dupilumab. * To evaluate the effect of dupilumab on improving participant-reported outcomes including health-related quality of life. * To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies.
Primary Outcome
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dupilumab
- DRUG Inhaled corticosteroid (ICS) therapy
- DRUG Albuterol/Salbutamol
- DRUG Levalbuterol/Levosalbutamol
Study Locations (20)
California
- Investigational Site Number 840109 - Bakersfield
- Investigational Site Number 840052 - Costa Mesa
- Investigational Site Number 840116 - Fresno
- Investigational Site Number 840045 - Long Beach
- Investigational Site Number 840011 - Los Angeles
- Investigational Site Number 840061 - Los Angeles
- Investigational Site Number 840097 - Los Angeles
- Investigational Site Number 840019 - Mission Viejo
- Investigational Site Number 840125 - Newport Beach
- Investigational Site Number 840041 - North Hollywood
- Investigational Site Number 840036 - Redwood City
- Investigational Site Number 840020 - Rolling Hills Estates
- Investigational Site Number 840074 - Roseville
- Investigational Site Number 840021 - San Jose
Arizona
- Investigational Site Number 840056 - Flagstaff
- Investigational Site Number 840099 - Gilbert
- Investigational Site Number 840087 - Scottsdale
Alabama
- Investigational Site Number 840047 - Birmingham
Arkansas
- Investigational Site Number 840132 - Little Rock
Colorado
- Investigational Site Number 840004 - Centennial
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,902 participants |
| Start Date | 2015-04-27 |
| Est. Completion | 2017-11-23 |
| Phase | Phase 3 |
What the finished NCT02414854 record still lists
NCT02414854 is an interventional study that assigns participants to a tested intervention. Its 1,902 participants enrollment target places it among the larger protocols in the corpus, above the 1,558-participant average among 374 other Asthma trials with a reported enrollment target (22% higher).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT02414854 names 20 study sites across 5 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT02414854 about?
NCT02414854 is a clinical study titled "Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)". Primary Objective: To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent asthma. Secondary Objectives: * To evaluate the safety and tolerability of dupilumab. * To evaluate the effect of dupilumab on improving participant-reported outcomes including health-re...
What is the current status of trial NCT02414854?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,902 participants. The study started on 2015-04-27. Estimated completion is 2017-11-23.
What conditions does trial NCT02414854 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT02414854?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG), Inhaled corticosteroid (ICS) therapy (DRUG), Albuterol/Salbutamol (DRUG), Levalbuterol/Levosalbutamol (DRUG).
Who is sponsoring clinical trial NCT02414854?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02414854 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02414854's enrollment target sits among peer trials
1,902 24th of 374 higher than 351 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- NCT06929806 · 1,900 participants · Phase 3
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
- NCT07228234 · 1,900 participants · NA
Evaluating Mammography Communication Approaches
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI